Acute myeloid leukemia with multilineage dysplasia
MONDO:0019456An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.
Also known as: AML with multilineage dysplasia, AML with myelodysplasia-related features, De novo acute myeloid leukaemia with multilineage dysplasia, De novo acute myeloid leukemia with multilineage dysplasia, acute myeloid leukaemia with myelodysplasia-related features, acute myeloid leukemia with myelodysplasia-related features
3112 clinical trials for this condition and its sub-types, 34 tagged with Acute myeloid leukemia with multilineage dysplasia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and see if it can slow or stop cancer growth. Researchers will also track how long patients live …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a cancer drug help patients with rare gene changes?
Disease control OngoingThis phase 2 trial tests the drug olaparib in 14 adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to treatment, and whose cancer has a specific change in the IDH gene. Olaparib is a pill that may block enzymes cancer cells need to …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Experimental combo aims to outsmart relapsed blood cancers
Disease control OngoingThis early-stage trial tests whether adding the immunotherapy drug ipilimumab to the chemotherapy drug decitabine is safe and tolerable for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back or stopped responding to treatment. About 54 p…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New chemo combo aims to stop leukemia return after transplant
Disease control OngoingThis phase 2 trial tests giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant in 72 patients with leukemia or myelodysplastic syndrome in remission. The goal is to prevent the cancer from coming back after the transplant while causing fewe…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo shows promise for MDS and AML
Disease control OngoingThis study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination is safe and effective. About 135 participants will take part in this early-…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Immunotherapy combo shows promise against tough blood cancer in seniors
Disease control OngoingThis study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug cocktail aims to beat Hard-to-Treat leukemia
Disease control OngoingThis phase 2 trial is testing a combination of two drugs—CPX-351 (a chemotherapy) and glasdegib (a targeted pill)—in 30 people with acute myeloid leukemia (AML) that is either linked to a prior blood disorder or caused by previous cancer treatment. The main goal is to see how man…
Phase 2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental combo targets hard-to-treat blood cancers
Disease control OngoingThis early-phase study tests two drugs—guadecitabine and atezolizumab—together in adults with myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or not responded to prior therapy. The goal is to find the safest dose and see if the combination can shrin…
Phase 1/2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Leukemia trial hopes to boost chemo with immune drug
Disease control OngoingThis phase 2 trial tests whether adding the drug pomalidomide to standard chemotherapy (daunorubicin and cytarabine liposome) helps people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 participants will rec…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can a targeted drug boost chemo for hard-to-treat blood cancers?
Disease control OngoingThis phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immunotherapy boosts chemo to wipe out hidden leukemia cells
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 participants will receive either chemo alone or chemo plus pembrolizumab. The …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo shows promise in early AML trial
Disease control OngoingThis early-phase study tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in adults with newly diagnosed acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works. About 24 p…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug combo shows promise for Tough-to-Treat leukemia
Disease control OngoingThis study tests whether adding pevonedistat to standard chemotherapy (cytarabine and idarubicin) can improve remission rates in people newly diagnosed with high-risk acute myeloid leukemia (AML). About 53 participants will receive the combination to find the best dose and check …
Phase 1/2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC